1) Clinical trials have shown that intraocular injections of anti-VEGF drugs are more effective than laser monotherapy for treating diabetic macular edema (DME), but nearly half of patients still require supplemental laser treatment after several months. 2) Subthreshold laser therapy, which causes no scarring or permanent retinal damage, has shown potential for reducing DME with better visual acuity outcomes compared to conventional laser therapy. 3) While anti-VEGF drugs provide excellent initial results for DME, laser therapy remains an important supplemental or primary treatment when edema persists or is located further from the fovea.